Skip to main content

Table 4 Summary of the mean radiobiological parameters for patients with specific cancer type

From: Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters

Cancer type \(T_{{\text{t}}}\) (days) \(T_{p}\) (days) \(T_{{\text{k}}}\) (days) \(\alpha\) (Gy−1) \(\alpha {/}\beta\) (Gy) BED (Gy) TCP (%) \(\Delta {\text{TLG}}_{{{\text{liver}}}}\)(%)
Breast 52.0
 ± 3.0
COV
≈ 6%
152
 ± 28
COV
≈ 18%
39.1
 ± 15.9
COV
≈ 41%
0.045
 ± 0.036
COV
≈ 80%
3.0
 ± 2.0
COV
≈ 67%
67.2
 ± 25.8
COV
≈ 38%
60.4
 ± 18.7
COV
≈ 31%
66.3
 ± 22.3
COV
≈ 34%
NET 45.3
 ± 5.1
COV
≈ 11%
162
 ± 33
COV
≈ 20%
32.1
 ± 9.5
COV
≈ 30%
0.33
 ± 0.18
COV
≈ 55%
7.87
 ± 2.0
COV
≈ 25%
106.7
 ± 54.1
COV
≈ 51%
46.8
 ± 12.0
COV
≈ 26%
50.7
 ± 13.1
COV
≈ 26%
CRC 49.4
 ± 2.4
COV
≈ 5%
129
 ± 19
COV
≈15%
23.5
 ± 8.3
COV
≈ 35%
0.010
 ± 0.005
COV
≈ 50%
14.1
 ± 8.9
COV
≈ 63%
36.0
 ± 15.3
COV
≈ 43%
28.2
 ± 12.7
COV
≈ 45%
7.7
 ± 33.1
COV
≈ 430%
Cholangiocarcinoma 46.3
 ± 1.4
COV
≈ 3%
236
 ± 67.2
COV
≈ 28%
28.3
 ± 10.5
COV
≈ 37%
0.040
 ± 0.022
COV
≈ 55%
2.38
 ± 1.21
COV
≈ 51%
45.7
 ± 12.8
COV
≈ 28%
53.1
 ± 16.6
COV
≈ 31%
63.5
 ± 18.0
COV
≈ 28%
Others 53.8
 ± 3.6
COV
≈ 7%
174
 ± 24
COV
≈ 14
32.2
 ± 6.2
COV
≈ 19%
0.100
 ± 0.040
COV
≈ 40%
4.28
 ± 0.94
COV
≈ 22%
40.9
 ± 11.5
COV
≈ 28%
35.3
 ± 9.5
COV
≈ 27%
42.9
 ± 11.0
COV
≈ 26%
  1. COV coefficient of variance